NDC product
Neostigmine Methylsulfate
NDC 23155-517 · Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Key facts
| Product NDC | 23155-517 |
|---|---|
| Proprietary name | Neostigmine Methylsulfate |
| Nonproprietary name | Neostigmine Methylsulfate |
| Substances | NEOSTIGMINE METHYLSULFATE |
| Dosage form | INJECTION |
| Route | INTRAVENOUS |
| Labeler | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA208230 |
| Pharmacologic classes | Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA] |
| Marketing start | Nov 25, 2022 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: